Form 4: Edgewise CFO Carruthers Reports Stock Transactions

Edgewise Therapeutics CFO R. Michael Carruthers reported recent transactions involving company common stock, including RSU vesting, a sell-to-cover tax sale, and new equity grants.

Summary

• R. Michael Carruthers, Chief Financial Officer of Edgewise Therapeutics, Inc. (EWTX), filed a Form 4 detailing recent equity transactions.
• On August 12, 2025, Carruthers acquired 5,781 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 1,428 shares were sold at an average price of $13.3924 to cover statutory tax withholding obligations related to the RSU vesting; this was a non-discretionary "sell-to-cover" transaction.
• Following these transactions, Carruthers directly beneficially owns 86,162 shares of common stock.
• New equity grants were made on August 12, 2025, including 26,875 Restricted Stock Units (RSUs) vesting in four equal annual installments beginning August 12, 2026.
• Additionally, 161,250 Stock Options (Right to Buy) were granted with an exercise price of $13.39, vesting 1/48th monthly starting September 12, 2025.
• The filing also notes 795 shares purchased on May 15, 2025, pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The filing primarily details routine executive compensation transactions, including RSU vesting and new equity grants, which are generally positive for aligning management incentives. The sale was non-discretionary for tax purposes, indicating no active divestment by the CFO.

Positives

• New RSU and stock option grants indicate continued compensation and alignment of management interests with shareholder value creation.
• The sale of shares was explicitly stated as a non-discretionary "sell-to-cover" transaction for tax purposes, not a discretionary sale by the Reporting Person.

Negatives

• A portion of shares were sold, even if for tax purposes, resulting in a slight reduction in direct beneficial ownership.

Future Outlook

The vesting schedules for newly granted Restricted Stock Units and stock options extend into future years, with RSUs vesting annually starting August 12, 2026, and stock options vesting monthly starting September 12, 2025, indicating ongoing executive compensation and potential future share acquisition.

Management Comments

• The sale of 1,428 shares represents the number of shares sold to cover statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.

Industry Context

Form 4 filings are standard regulatory disclosures for executive compensation and insider transactions across all industries, including the biotechnology and pharmaceutical sector where Edgewise Therapeutics operates. These filings provide transparency into how executives are compensated and manage their equity holdings.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as components of executive compensation is a common practice within the biotechnology and pharmaceutical industry, aligning executive incentives with long-term company performance.
• The "sell-to-cover" mechanism for tax withholding is a standard, non-discretionary transaction frequently observed in executive equity compensation plans across publicly traded companies.

Stakeholder Impact

• Shareholders: The issuance of new equity awards could lead to minor dilution over time as they vest and are exercised, but also serves to align executive interests with shareholder value creation. The sell-to-cover transaction is a routine event for tax compliance.
• Employees: The mention of the 2021 Employee Stock Purchase Plan indicates broader employee equity participation, which can foster employee alignment and retention.

Next Steps

• Continued vesting of 161,250 stock options monthly, beginning September 12, 2025.
• Continued vesting of 26,875 Restricted Stock Units annually, beginning August 12, 2026.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Form 4, Insider Trading, Stock Transactions, RSU, Stock Option, Executive Compensation, R. Michael Carruthers, CFO